Rain oncology stock.

Oct 13, 2023 · Rain Oncology ( NASDAQ: RAIN) has received an acquisition proposal from Concentra Biosciences, an affiliate of Tang Capital Partners, for $1.25/share in cash. The clinical-stage micro-cap cancer ... [relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of Rain Therapeutics Inc. (RAIN) Rain Therapeutics Inc. is a biotechnology company focused on targeted therapies for patients with cancer. The company was founded in 2017 and is headquartered in Newark, California. Since its inception, Rain Therapeutics has …Description. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology.WebMay 30, 2023 · Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.

Nov 22, 2023 · Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an annualized return of -73.98% (not including any dividends or dividend reinvestments).

May 22, 2023. NEWARK, Calif., May 22, 2023 – Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and ...Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at $7,240,014.60.

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.Try our powerful stock tools to help compare investments and get ideas. View Our Research Providers. Find out about our industry leading research providers. ... Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023;With the company starting 2023 with 8,725 employees, that’s an 11.5% workforce reduction. Story. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut ...Stock Price Forecast The 4 analysts offering 12-month price forecasts for Rain Oncology Inc have a median target of 1.38, with a high estimate of 2.00 and a low estimate of 1.00.WebThe offer is just the latest example of Concentra hoping to snap up a troubled biotech this year, after a reach out to Rain Oncology last month. Tang has already scored success when Concentra used ...

Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc.,...

Nov 9, 2023 · NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing ...

Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ...Track Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Nov 24, 2023 · RAIN News Today | Why did Rain Oncology stock go up today? S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) Turned down for a loan, business owners look to family and even ... Cardiff Oncology is a prime takeover target heading into 2022. The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. Four ...Rain Oncology ( NASDAQ: RAIN) shed ~9% in the morning hours Tuesday after announcing layoffs, the departure of the company’s chief medical officer, and changes to its clinical programs for lead ...Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low.

Rain Oncology Inc 52 week high is $14.48 as of November 24, 2023. What is the 52-week low for Rain Oncology Inc? 52 week low is the lowest price of a stock in the past 52 weeks, or one year.Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Oncology stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at $7,240,014.60.0.82%. ARM. 3.90%. Get the latest Mural Oncology PLC (MURA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...Events. News & press releases. Investors. Overview. Stock Information. Analyst Coverage. Stock Quote & Chart. Historical Price Lookup. Investment Calculator.NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...Stock Ward (E320) Zone E, 3rd floor - room 20 Plastic Surgery Ward Call 01245 513922. Visiting times are between 11am to 9pm . Stroke Unit (A302) ... Oncology, Haematology Ground Floor, Prittlewell Building. Call 01702 435555 ext 6255. Endoscopy Unit Mz, Tower Block. Call 01702 385096.22 May 2023 ... Milademetan in Liposarcoma: © Dr_Microbe - stock.adobe.com ... Rain oncology announces topline results from phase 3 MANTRA trial of ...

The stock has increased 17.9% in price over the past month and closed Friday's trading session at $3.03. Each of the four Wall Street analysts that rated ELEV rated it Buy. The 12-month median ...A high-level overview of Rain Oncology Inc. (RAIN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Nov 4, 2022 · Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The shares are being sold at an offering price of $5.83 per ... Top Pharmaceuticals & Drugs Stocks in India by Market Capitalisation: Get the List of Top Pharmaceuticals & Drugs Companies in India (BSE) based on Market CapitalisationRain Oncology Inc (NASDAQ: RAIN) announced topline Phase 3 MANTRA data of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS). The study did not meet its primary endpoint of ...According to the issued ratings of 12 analysts in the last year, the consensus rating for Rain Oncology stock is Hold based on the current 10 hold ratings and 2 buy ratings for RAIN. The average twelve-month price prediction for Rain Oncology is $17.00 with a high price target of $24.00 and a low price target of $11.00.Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Rain Oncology Inc have a median target of 1.38, with a high estimate of 2.00 and a low estimate of 1.00. The median ...‍ Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate patient population most likely to benefit from treatment. Rain is focused on a few critical objectives: (1) strive to greatly enhance probabilities of therapeutic ...

The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 20.91% change from the last ...

May 22, 2023 · Rain Oncology ( NASDAQ: RAIN) fell ~81% in the pre-market Monday after announcing that its lead product candidate, milademetan, did not reach the primary endpoint in a Phase 3 trial for patients ...

The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 20.91% change from the last ...Dec 29, 2022 · The number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology. PFS (Primary): Approximately 105 events by blinded central review to trigger primary analysis. OS, ORR, DCR, DOR. Safety. TP53. Overview. MDM2 gene CN of ≥8. Patients enrolled based on local NGS for CN, centrally confirmed by Rain's diagnostic partner, Tempus. Evaluable tumor types included: lung, breast, biliary, pancreatic and other select ...Get Rain Oncology Inc (RAIN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsWhat is the target price for Rain Oncology (RAIN) stock? The latest price target for Rain Oncology ( NASDAQ: RAIN) was reported by Citigroup on Monday, September 18, 2023. The analyst firm set a ...Kura Oncology stock price target raised to $56 from $44 at Wedbush. Dec. 7, 2020 at 7:17 a.m. ET by Tomi Kilgore.Rain Oncology's stock has fallen near 25% following postponement of milademetan's top-line results and increased net losses reported in Q4 2022 and full year 2022. Click here to read more.WebDec 1, 2023 · View Rain Oncology Inc RAIN investment & stock information. Get the latest Rain Oncology Inc RAIN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

BioPharma Dive news delivered to your inbox. Get the free daily newsletter read by industry experts. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.1.05. +0.03. +2.94%. Get Rain Oncology Inc (RAIN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.A high-level overview of Loxo Oncology (LOXO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.On average, Wall Street analysts predict. that Rain Oncology's share price could reach $1.33 by Sep 18, 2024. The average Rain Oncology stock price prediction forecasts a potential upside of 22.29% from the current RAIN share price of $1.09. Instagram:https://instagram. mutual funds that give monthly dividendsapple stock a buyzynerba pharmaceuticals stockactivision blizzard stocks Get the latest Rain Oncology Inc. (RAIN) stock news and headlines to help you in your trading and investing decisions. NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to ...Web bito stock price today400 000 house down payment Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ... companies financial planning The global pharmaceutical industry is expected to generate $1.15 trillion in sales in 2023, according to Statista. The oncology segment alone should see $188.2 billion in sales this year. The ...Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc.,...NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...